Tóm tắt
Objectives: To evaluate the efficacy and safety of the TS1-Cisplatin regimen in the first-line treatment of metastatic gastric cancer patients.
Methods: 38 eligible patients were treated with TS1-Cisplatin at Hanoi Medical University Hospital from January 2018 to December 2021.
Results: The mean age was 57.4. The male to female ratio was 3.2:1. Most patients had good performance status (PS 0 or PS 1 - 84.2%). Most received a dose rate from 85% to 100% of the standard dose (78.9%). After six cycles, the complete response rate was 13.2%, and the partial response rate was 42.1%. The median progression-free survival was 5.7 months, and the median overall survival was 13.5 months. Neutropenia was the most common adverse event (52.6%), with 13.1% in grade 3-4. Diarrhea accounted for 36.8%, with only one case in grade 3 (2.6%). Only one patient experienced hand-foot syndrome (2.6%).
Conclusion: The TS1-Cisplatin regimen in metastatic gastric cancer demonstrated a good response rate while being safe and tolerable.
Tài liệu tham khảo
Sung H, Ferlay J, Siegel RL et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA: a cancer journal for clinicians. 2021;71(3): 209-249.
Kobayakawa M, Kojima Y. Tegafur/ gimeracil/ oteracil (S- 1) approved for the treatment of advanced gastric cancer in adults when given in combination with cisplatin: a review comparing it with other fluoropyrimidine-based therapies. Onco Tagets and Ther. 2011;4:193-201
Wagner AD, Grothe W, Haerting J, Kleber G et al. Chemotherapy in advanced gastric cancer: a systematic review and meta-analysis based on aggregate data. J Clin Oncol. 2006; 24(18): 2903-2909.
Koizumi W, Narahara H et al. S-1 plus cisplatin versus S-1 alone for first-line treatment of advanced gastric cancer (SPIRITS trial): a phase III trial. Lancet Oncol. 2008;9: 215-221.
Boku N, Yamamoto S, Fukuda H et al. Fluorouracil versus combination of irinotecan plus cisplatin versus S-1 in metastatic gastric cancer: a randomised phase 3 study. The Lancet Oncology. 2009;10(11): 1063-1069.
Ajani JA, Buyse M, Lichinitser M et al. Combination of Cisplatin/S-1 in the treatment of patients with advanced gastric or gastroesophageal adenocarcinoma: Results of noninferiority and safety analyses compared with Cisplatin/5- fluorouracil in the First-Line Andvanced Gastric Cancer Study. European Journal of Cancer. 2013;49:3616-3624.
Khanh Ha Nguyen. Evaluating the treatment results of TCX regimen in recurrent or metastatic gastric cancer. Medical Thesis. 2019. Hanoi Medical University.
Nhu Hanh To. Evaluating the treatment results of EOX regimen in inoperable advanced gastric cancer. Medical Thesis. 2012. Hanoi Medical University.
Van Hung Nguyen, Hong Thang Vu, Hai Dang Do, et al. Evaluating the treatment results of FOLFIRI regimen in advanced gastric cancer. Vietnam Medical Journal. 2017;459.
Li Y, Qiu M, Xu J. S-1 plus cisplatin versus fluorouracil plus cisplatin in advanced gastric or gastro-esophageal junction adenocarcinoma patients: a pilot study. Oncotarget. 2015;6(33):35107-35115.
Boku N, Yamamoto S, Fukuda H et al. Fluorouracil versus combination of irinotecan plus cisplatin versus S-1 in metastatic gastric cancer: a randomized phase 3 study. The Lancet Oncology. 2009;10(11): 1063-1069.
He M, Wu W, Wang F et al. S-1-Based Chemotherapy versus Capecitabine-Based Chemotherapy as First-Line Treatment for Advanced Gastric Carcinoma: A Meta-Analysis. PLoS ONE. 2013;8(12): e8279
| Đã xuất bản | 25-03-2022 | |
| Toàn văn |
|
|
| Ngôn ngữ |
|
|
| Số tạp chí | Số 78 (2022) | |
| Phân mục | Nghiên cứu | |
| DOI | 10.38103/jcmhch.78.3 | |
| Từ khóa | Advanced gastric cancer, TS1, cisplatin Advanced gastric cancer, TS1, cisplatin |
công trình này được cấp phép theo Creative Commons Attribution-phi thương mại-NoDerivatives 4.0 License International .
Bản quyền (c) 2022 Tạp chí Y học lâm sàng Bệnh viện Trung Ương Huế